Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled study of oral RS-C1001 in mixed hyperlipidemia
CTR20263703Phase 2Active
- Sponsor
- Ruisen Biotechnology
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RS-C1001 in combined dyslipidaemia, sponsored by Ruisen Biotechnology. Started Sep 2026; status: active.
02
Drugs
RS-C1001
03
Conditions
combined dyslipidaemia
Beyond the preview
Go deeper on CTR20263703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263703.